UrsaNav trials eLoran as vital GNSS backup using ADVA’s grandmaster clock solution
27.7.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that UrsaNav and ADVA have conducted an enhanced long-range navigation (eLoran) field trial using UrsaNav’s eLoran receiver and ADVA’s Oscilloquartz grandmaster clock technology. The successful demo shows that eLoran offers a robust and reliable backup for GPS and other GNSS and could be used to provide an assured position, navigation, and timing (PNT) service. The trial follows US federal executive order 13905 aimed at strengthening national resilience through PNT services, including protecting critical infrastructure such as electrical power grid and communication networks from rising cyber threats. By harnessing ADVA’s flexible OSA 5420 Series, designed with assured PNT (aPNT) technology, UrsaNav has shown that eLoran can provide a new layer of protection and significantly boost timing resilience and security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005101/en/
ADVA’s synchronization technology is key for critical infrastructure that needs ultra-reliable aPNT solutions (Photo: Business Wire)
“The success of this field trial demonstrates how eLoran, as part of ADVA’s assured PNT solution, can serve as a crucial backup for GPS. We have shown how our technology enables ADVA’s grandmaster clock to receive UTC timing from the eLoran system for a period of several days with the same accuracy and stability as GPS. Of course, this capability is extensible to other GNSS as well. eLoran is far less vulnerable to unintentional jamming and spoofing disruptions or intentional attacks, thereby delivering nanosecond precision with even more resilience,” said Charles Schue, CEO, UrsaNav. “By partnering with ADVA, we’ve been able to show that our eLoran receiver interoperates with the best network timing toolkit available. The OSA 5420 Series is a great product – highly efficient and easy to operate. Together with ADVA, we’re paving the way for tomorrow’s more robust assured PNT synchronization architecture.”
Across the globe, essential services and entire industries are increasingly reliant on GNSS for PNT information. But these satellite systems are inherently susceptible to interference, which could have disastrous consequences. A major disruption may result in billions of dollars of economic damage as well as a serious risk of loss of life. eLoran is one of the key technologies that could provide protection, with governments including the US exploring its potential as an alternative PNT source. UrsaNav’s latest trial harnessed the OSA 5420 Series grandmaster clock with inbuilt GNSS receiver. Timing stability from GPS was measured for several days. This was then replaced with eLoran for the same period with no loss of stability. What’s more, the test was conducted indoors where GNSS signals are not usually available, potentially extending the availability of precise UTC timing to many more environments.
“Commercially available GNSS jammers and spoofers are easy and cheap for attackers to construct. That’s part of the reason why we’re seeing a growing number of incidents across the world of blocked or misleading signals. If power utilities, enterprises, service providers and governments continue to rely on GNSS alone, it’s only a matter of time before the consequences become very serious. That’s why we’re committed to tackling GNSS vulnerabilities with advanced technologies like our ePRTC offering, cesium atomic clocks and our optical timing channel solution,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Now that UrsaNav has demonstrated the power of our OSA 5420 Series to utilize eLoran in the event of outages, we have another very important tool to ensure the quality and availability of time-sensitive services.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
About UrsaNav
Ursa Navigation Solutions (“UrsaNav”) is the world’s leading supplier of Low Frequency PNT solutions, with proven performance delivering the latest technology for eLoran systems, including transmission, control, monitoring, and reference site equipment. From initial concept through operational certification, UrsaNav provides every aspect of the provider or user experience, including commercial and military PNT solutions, critical infrastructure protection, and legacy system transformation. www.ursanav.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005101/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
